Barclays PLC Bio N Tech Se Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Bio N Tech Se stock. As of the latest transaction made, Barclays PLC holds 88,706 shares of BNTX stock, worth $10.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

88,706

Previous 36,868 140.6%

Holding current value

$10.5 Million

Previous $3.4 Million 109.59%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$80.36 - $102.87 $4.17 Million - $5.33 Million	51,838 Added 140.6%	88,706 $7.13 Million
Q1 2024 May 15, 2024	BUY	$88.96 - $112.35 $1.17 Million - $1.47 Million	13,122 Added 55.26%	36,868 $3.4 Million
Q4 2023 Feb 15, 2024	SELL	$90.91 - $112.75 $1.18 Million - $1.46 Million	-12,933 Reduced 35.26%	23,746 $2.51 Million
Q3 2023 Nov 07, 2023	SELL	$98.5 - $125.08 $3.6 Million - $4.57 Million	-36,548 Reduced 49.91%	36,679 $3.99 Million
Q2 2023 Aug 03, 2023	SELL	$102.58 - $129.66 $2.87 Million - $3.62 Million	-27,932 Reduced 27.61%	73,227 $7.91 Million
Q1 2023 May 04, 2023	BUY	$122.57 - $153.67 $3.05 Million - $3.82 Million	24,867 Added 32.59%	101,159 $12.6 Million
Q4 2022 Feb 13, 2023	BUY	$118.43 - $186.05 $1.29 Million - $2.03 Million	10,898 Added 16.67%	76,292 $11.5 Million
Q3 2022 Nov 03, 2022	SELL	$127.65 - $183.11 $10.6 Million - $15.2 Million	-82,879 Reduced 55.9%	65,394 $8.82 Million
Q2 2022 Aug 12, 2022	SELL	$123.25 - $186.24 $557,829 - $842,922	-4,526 Reduced 2.96%	148,273 $22.1 Million
Q1 2022 May 16, 2022	BUY	$126.25 - $231.85 $19.3 Million - $35.4 Million	152,799 New	152,799 $26.1 Million

Others Institutions Holding BNTX

# of Institutions

328

Shares Held

40.6M

Call Options Held

845K

Put Options Held

1.23M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.8B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account